Beneluxa Agreement

The agreement was reached in August in the Netherlands and in September in Belgium in airtime on a confidential price agreement on Spinraza`s list price of 499,800 euros for a one-year salary, although it is still unknown. The first successful collective price negotiation was carried out in July 2018 for Biogen`s spinraza drug. A confidential price agreement has been reached between Biogen, Belgium and the Netherlands to pay Spinraza back temporarily until December 2020, when real evidence is gathered. The Spinraza agreement is revolutionary, as it is the first successful international joint negotiation that allows the inclusion of a drug in the basic hedging packages of two different countries under similar financial parameters. This was the second chance for the Benelux – its first joint evaluation of Vertex orkambi failed without a market access agreement. But Biogen and Beneluxa both welcomed the process, which is currently ending on a voluntary basis. Dutch Health Minister Bruno Bruins said at the time of the July agreement: « First of all, the positive result is wonderful news for young ADM patients and their families, both in the Netherlands and Belgium. » It is also a very clear and promising example of the benefits of price negotiation and pharmaceutical policy cooperation. Biogen`s willingness to participate in a common process and discover the benefits of rapid access to multiple markets at the same time is a positive development. So I hope that other companies will follow suit. Given that the collection of real evidence (RWE) is part of the Spinraza agreement, I wonder if this will be the norm in the future – and hand in hand with results-based repayment agreements. Marcel says that the Benelux is in favour of EU cooperation, but considers that its alliance is much less problematic, because it stems from a common need in each country.

« The difference is that benalous cooperation is a process led by the Member States…. As you know in Europe, there are differing views on the scope of a Commission-oriented approach with a central regulation.